Abstract
Oculopharyngeal muscular dystrophy (OPMD) is a late-onset progressive muscle disorder caused by a poly-alanine expansion mutation in the Poly(A) Binding Protein Nuclear 1 (PABPN1). The molecular mechanisms that regulate disease onset and progression are largely unknown. In order to identify molecular pathways that are consistently associated with OPMD, we performed an integrated high-throughput transcriptome study in affected muscles of OPMD animal models and patients. The ubiquitin-proteasome system (UPS) was found to be the most consistently and significantly OPMD-deregulated pathway across species. We could correlate the association of the UPS OPMD-deregulated genes with stages of disease progression. The expression trend of a subset of these genes is age-associated and therefore, marks the late onset of the disease, and a second group with expression trends relating to disease-progression. We demonstrate a correlation between expression trends and entrapment into PABPN1 insoluble aggregates of OPMD-deregulated E3 ligases. We also show that manipulations of proteasome and immunoproteasome activity specifically affect the accumulation and aggregation of mutant PABPN1. We suggest that the natural decrease in proteasome expression and its activity during muscle aging contributes to the onset of the disease.
Highlights
Oculopharyngeal muscular dystrophy (OPMD) is a lateonset progressive muscle disorder for which the underlying molecular mechanisms are largely unknown
Genome-wide expression profiles from the Drosophila and mouse OPMD models [6,11] were integrated with the expression profiles of heterozygous OPMD carriers
Since Poly(A) Binding Protein Nuclear 1 (PABPN1) is ubiquitously expressed in every cell but the phenotype is limited to muscle cells this suggests that ubiquitin-proteasome system (UPS) deregulation confers the muscle-specific pathogenesis of OPMD
Summary
Oculopharyngeal muscular dystrophy (OPMD) is a lateonset progressive muscle disorder for which the underlying molecular mechanisms are largely unknown. This autosomal dominant muscular dystrophy has an estimated prevalence of 1 in 100,000 worldwide [1]. Hino et al [12] suggested that the extent of muscle symptoms caused by expPABPN1 depends on the expression level. It is not known whether the massive transcriptional changes in affected muscles of the A17.1 OPMD model [11] are due to the high over-expression of expPABPN1 or if they are common with transcriptional changes in OPMD patients
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.